CDKN2A and atherosclerosis: Similarly, despite limitations in their use as senescence markers in atherosclerosis, there was no effect of ABT-263 treatment on expression of p16 or a range of SASP cytokine mRNAs in the vessel wall (Figure 5F), raising the possibility that some of the effects of ABT-263 may not be through senolysis.